<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130244</url>
  </required_header>
  <id_info>
    <org_study_id>GIW 16-001</org_study_id>
    <nct_id>NCT03130244</nct_id>
  </id_info>
  <brief_title>Endoscopic Procedure for Jejunal to Ileal Diversion to Treat Type 2 Diabetes</brief_title>
  <official_title>A Trial for an Endoscopic Procedure for Jejunal to Ileal Diversion to Treat Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Windows, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GI Windows, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study will monitor changes in HbA1c for subjects in Intervention arm vs control arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Single-Center, Parallel-group, Open-label Pilot Study to Evaluate the Safety and
      Effectiveness of the GI Windows Incisionless Anastomosis System (IAS) When Used to Create a
      Dual-path Enteral Bypass Compared with Medical Therapy Alone To Effect Glycemic Control in
      Obese Patients with Type 2 Diabetes Mellitus (T2DM)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in HbA1c</measure>
    <time_frame>12 months</time_frame>
    <description>The primary effectiveness endpoint is Mean change in HbA1c from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Weight</measure>
    <time_frame>12 months</time_frame>
    <description>12 month weight loss measured as a percent of total body weight loss and excess weight loss (using the BMI method) as well as weight/BMI change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving remission</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects experiencing diabetes remission and/or partial remission at 12 months (as defined by the American Diabetes Association)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in diabetes medication</measure>
    <time_frame>12 months</time_frame>
    <description>Change in diabetes medication requirements from baseline to 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Device Placement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this arm will receive the Incisionless Magnet Anastomosis System and an anastomosis will be created.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients in this arm will receive the best medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Incisionless Magnet Anastomosis System</intervention_name>
    <description>The IMAS will be placed using an endoscope in the jejunum and ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the jejunum to ileum treats Type 2 diabetes.</description>
    <arm_group_label>Device Placement</arm_group_label>
    <other_name>IMAS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Medical Management</intervention_name>
    <description>The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) 30 to 45.

          -  Subject Type 2 Diabetes Criteria:

               1. T2DM diagnosis ≥6 months but &lt; 10 years

               2. On 1 or more oral diabetes medications (with one at the minimum recommended
                  therapeutic dose)

               3. Hemoglobin A1C (HbA1c) between and including 7.5 and 10.0% (58 mmol/mol to 86
                  mmol/mol) at time of enrollment and has had a stable HbA1c over a 3-month period
                  (i.e., &lt;0.3% reduction)

               4. Stable medication regimen (i.e., no change in diabetes medications) for at least
                  3 months prior to Screening Visit.

          -  If subject has obesity-related comorbidities such as hypertension, dyslipidemia, and
             sleep apnea, these comorbidities must be well-controlled.

          -  Able to understand and sign informed consent document

          -  Has primary care physician and/or endocrinologist who follows patient for all comorbid
             conditions

        Exclusion Criteria:

          -  Known or suspected allergy to nickel or titanium or Nitinol

          -  Type 1 Diabetes

          -  Use of injectable insulin

          -  Uncontrolled T2DM Fasting glucose ≥ 200 mg/dl (11.1 mmol/L)

          -  Probable insulin production failure, defined as fasting serum C Peptide &lt;1 ng/mL (0.3
             nmol/l)

          -  Any documented conditions for which endoscopy/colonoscopy would be contraindicated.

          -  Contraindication to general anesthesia

          -  Congenital or acquired anomalies of the GI tract, including atresias, stenosis or
             malrotation.

          -  Previous abdomino-pelvic surgery that may result in adhesions or anatomical changes
             that may interfere with placement of the GIW device.

          -  Previous technically difficult or failed colonoscopy or endoscopy

          -  If on metformin, history of polycystic ovarian syndrome (PCOS)

          -  Unable or unwilling to perform home blood glucose monitoring

          -  History of or suspected gastrointestinal disease (e.g. cirrhosis, inflammatory bowel
             disease)

          -  Diagnosis of active malignancy (i.e. not in remission) with the exception of squamous
             or basal cell carcinoma of the skin

          -  Previous surgical or endoscopic treatment for obesity including but not restricted to
             intragastric balloons, endoscopic suturing or stapling procedures, malabsorptive
             sleeves.

          -  Specific genetic or hormonal cause of obesity (e.g. Prader-Willi syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf H Buxhoeveden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bariatric Surgeon at Hospital Aleman</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter J Lukin</last_name>
    <phone>9787610183</phone>
    <email>peter.lukin@giwindows.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Fagnant</last_name>
    <phone>4013920287</phone>
    <email>afagnant@verizon.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aleman Hospital</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf H Buxhoeveden, MD</last_name>
      <phone>541148277000</phone>
      <phone_ext>2808</phone_ext>
      <email>rbuxhoeveden@hospitalaleman.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

